



CME Session 8

Radiopharmaceutical Sciences Committee

Monday, October 6, 16:45 – 18:15

Session Title

Radiotheranostics 2.0: The Power of Emerging Radioisotopes in Translating Imaging into Personalized Radiotherapy

Chairpersons

Filipe Elvas (Antwerp, Belgium)

Karolien Goffin (Leuven, Belgium)

Programme

- 16:45 – 17:05 **Ken Herrmann** (Essen, Germany): Most promising radionuclides for immediate clinical impact
- 17:05 – 17:30 **Michelle Ma** (London, United Kingdom): Radiometals for imaging and radioligand therapy
- 17:30 – 17:55 **Chiara Favaretto** (Verona, Italy): Terbium-based theranostic pairs
- 17:55 – 18:15 **Andrei Iagaru** (Stanford, United States of America): Bringing theranostics to the clinic: main clinical issues

Educational Objectives

1. Understanding the fundamentals of radiotheranostics
2. Exploring emerging radioisotopes and their clinical applications
3. Application of theranostic pairs in personalized treatment strategies
4. Understanding current clinical issues and future directions

Summary

This Continuing Medical Education (CME) session explores the rapidly evolving field of radiotheranostics, emphasizing the integration of molecular imaging and targeted radionuclide therapy to advance personalized cancer treatment. With emerging radioligands and radioisotopes offering improved tumor targeting, enhanced therapeutic efficacy, and reduced toxicity, this session will provide healthcare professionals in nuclear medicine, oncology, and medical physics with the latest insights on their applications.

Key Words

Radiotheranostics; Molecular imaging; Targeted radionuclide therapy; Nuclear medicine